Gautam U. Mehta

Gautam U. Mehta

Auto-generated profile, based on publicly available information

Gautam U. Mehta

From the Oncology Center of Excellence (G.U.M., R.P.) and the Office of the Commissioner (N.N.B., R.M.C.), Food and Drug Administration, Silver Spring, MD

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2017 in Nature
Verified
Journal Article
Closed access
PDF file
SPShashank J. Patel
Shashank J. Patel
NSNeville E. Sanjana
Neville E. Sanjana
RKRigel J. Kishton
Rigel J. Kishton
AEArash Eidizadeh
Arash Eidizadeh
SVSuman K. Vodnala
Suman K. Vodnala
NRNicholas P. Phillip Restifo
Nicholas P. Phillip Restifo

1 January 2016 in Cell Metabolism
Verified
Journal Article
Closed access
MSMadhusudhanan Sukumar
Madhusudhanan Sukumar
JLJie Liu
Jie Liu
GMGautam U. Mehta
Gautam U. Mehta
SPShashank J. Patel
Shashank J. Patel
RRRahul Roychoudhuri
Rahul Roychoudhuri
NRNicholas P. Phillip Restifo
Nicholas P. Phillip Restifo

21 June 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JFJaleh Fallah
Jaleh Fallah
MBMichael H. Brave
Michael H. Brave
CWChana Weinstock
Chana Weinstock
GMGautam U. Mehta
Gautam U. Mehta
DBDiana Bradford
Diana Bradford
JBJulia A. Beaver
Julia A. Beaver
On August 13, 2021, the FDA approved belzutifan (WELIREG, Merck), a first-in-class hypoxia-inducible factor (HIF) inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. The FDA granted approval based on the clinically meaningful effects on overall response rate (ORR) observed in patients enrolled in Study MK-6482-004. All 61 patients had VHL-associated RCC; some also had CNS hemangioblastomas and/or pNET. For VHL disease–associated RCC, ORR was 49% [95% confidence interval (CI), 36–62], median duration of response (DoR) was not reached, 56% of responders had DoR ≥12 months, and median time to response was 8 months. Twenty-four patients had measurable CNS hemangioblastomas with an ORR of 63% (95% CI, 41–81), and 12 patients had measurable pNET with an ORR of 83% (95% CI, 52–98). For these tumors, median DoR was not reached, with 73% and 50% of patients having response durations ≥12 months for CNS hemangioblastomas and pNET, respectively. The most common adverse reactions, including laboratory abnormalities, reported in ≥20% were anemia, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea. Belzutifan can render some hormonal contraceptives ineffective and can cause embryo-fetal harm during pregnancy. This article summarizes the data and the FDA thought process supporting traditional approval of belzutifan for this indication.

19 August 2016 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
GMGautam U. Mehta
Gautam U. Mehta
RLRussell R. Lonser
Russell R. Lonser
Pituitary adenomas are one of the most common primary central nervous system tumors and have an estimated prevalence of 17%. Approximately half of pituitary adenomas secrete distinct pituitary hormones (most often prolactin, growth hormone, or adrenocorticotropic hormone). While these tumors are histologically benign, they have potent endocrine effects that lead to significant morbidity and shortened lifespan. Because of their pathophysiologic endocrine secretion and anatomic location near critical neural/vascular structures, hormone-secreting pituitary adenomas require defined management paradigms that can include relief of mass effect and biochemical remission. Management of hormone-secreting pituitary adenomas involves a multidisciplinary approach that can incorporate surgical, medical, and/or radiation therapies. Early and effective treatment of hormone-secreting pituitary adenomas can reduce morbidity and mortality. Consequently, understanding clinical features as well as therapeutic options in the context of the specific biological features of each type of hormone-secreting pituitary adenoma is critical for optimal management.

23 December 2009 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
AAAshok R. Asthagiri
Ashok R. Asthagiri
GMGautam U. Mehta
Gautam U. Mehta
LZLeor Zach
Leor Zach
XLXiaobai Li
Xiaobai Li
JBJohn A. Butman
John A. Butman
RLRussell R. Lonser
Russell R. Lonser
To determine the effectiveness of stereotactic radiosurgery (SRS) treatment to central nervous system (CNS) hemangioblastomas in von Hippel–Lindau disease (VHL), we analyzed long-term results in VHL patients treated with SRS. Patients were enrolled in a prospective VHL natural history study, undergoing SRS treatment of CNS hemangioblastomas. Treatment regimens, serial clinical evaluations, and longitudinal imaging data were analyzed. Twenty VHL patients (10 males and 10 females) underwent SRS treatment of 44 CNS hemangioblastomas (39 cerebellar and 5 brainstem). Mean (±SD) age at treatment was 37.5 ± 12.0 years (range: 13–67). Mean follow-up was 8.5 ± 3.2 years (range: 3.0–17.6 years). All patients were alive at last follow-up. Mean treated tumor volume was 0.5 ± 0.7 cm3 (range: 0.01–3.6 cm3). Mean prescription dose was 18.9 Gy (range: 12–24 Gy) at the tumor margin. Local control rate at 2, 5, 10, and 15 years after SRS treatment was 91%, 83%, 61%, and 51%, respectively. Univariate analysis did not identify variables associated (P > .05) with worse tumor control at last follow-up. Thirty-three percent of SRS-treated small (<1.0 cm diameter), asymptomatic tumors progressed over a long-term follow-up. There were no long-term adverse radiation effects. Although SRS treatment of hemangioblastomas in VHL has a low risk for adverse radiation effects, it is associated with diminishing control over a long-term follow-up. These results indicate that SRS should not be used to prophylactically treat asymptomatic tumors and should be reserved for the treatment of tumors that are not surgically resectable.

29 August 2017 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
GMGautam U Mehta
Gautam U Mehta
DDDale Ding
Dale Ding
MPMohana Rao Patibandla
Mohana Rao Patibandla
HKHideyuki Kano
Hideyuki Kano
NSNathaniel Sisterson
Nathaniel Sisterson
JSJason P. Sheehan
Jason P. Sheehan
Context Cushing’s disease (CD) due to ACTH-secreting pituitary tumors can be a management challenge. Objective To better understand the outcomes of stereotactic radiosurgery (SRS) for CD and define its role in management. Design International, multicenter, retrospective cohort analysis. Setting Ten medical centers participating in the International Gamma Knife Research Foundation (IGKRF). Patients Patients with CD with greater than 6 months endocrine follow-up. Intervention SRS using Gamma Knife radiosurgery. Main outcome measures The primary outcome was control of hypercortisolism (defined as normalization of free urinary cortisol). Radiologic response and adverse radiation effects were recorded. Results 278 patients met inclusion criteria, with mean follow-up of 5.6 years (0.5-20.5 years). Twenty-two patients received SRS as a primary treatment for CD. Mean margin dose was 23.7 Gy. Cumulative initial control of hypercortisolism was 80% at 10 years. Mean time to cortisol normalization was 14.5 months. Recurrences occurred in 18% with initial cortisol normalization. Overall, the rate of durable control of hypercortisolism was 64% at 10 years, and 68% among patients who received SRS as a primary treatment. Adverse radiation effects included hypopituitarism (25%) and cranial neuropathy (3%). Visual deficits were related to treatment of tumor within the suprasellar cistern (P=0.01), while both visual (P<0.0001) and non-visual cranial neuropathy (P=0.02) were related to prior pituitary irradiation. Conclusions SRS for CD is well-tolerated and frequently results in control of hypercortisolism. However, recurrences can occur. SRS should be considered for patients with persistent hypercortisolism after pituitary surgery and as a primary treatment in those unfit for surgery. Long-term endocrine follow-up is essential after SRS.